Business Wire

TSURUMI-BREWING

30.11.2015 15:01:49 CET | Business Wire | Press release

Share
Sales to Begin of Tsurumi Brewing's SUSHI SAKE—A Sake Expressly for Sushi, Japan's Culinary Gift to the World

Founded in 1873, Tsurumi Shuzou Co., Ltd. (hereinafter, Tsurumi Brewing ) have developed SUSHI SAKE Kamitsuru Junmai Daiginjo (junmai means it is made with only rice products and no added alcohol, and daiginjo refers to the fact that the rice has been milled to fifty percent or less of its weight during the process), based on the concept of having a Japanese sake to go with sushi, in conjunction with the boom we are currently seeing in sake popularity outside of Japan. Sales have begun in November of 2015.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151130005179/en/

Product info: http://www.tsurumi-jp.com/sushi_sake/en

Priced at ¥12,000 per bottle, SUSHI SAKE Kamitsuru Junmai Daiginjo, a Sake for Sushi

Tsurumi Brewing, a company that produces and sells sake, began sales of SUSHI SAKE Kamitsuru Junmai Daiginjo in November, working from the notion that sake could serve to improve the wonderful taste of sushi, beloved world-wide, and representative of Japan’s food culture.

We designed SUSHI SAKE to hold back the raw odors unique to the fish used in sushi on your palette while paying particular attention to the balance for the earthier, umami flavors. By offering a crisp finishing tone, you will find it goes very well with sushi by preparing you for the next bite.

Developed by a Venerable Japanese Sake Brewer

Development of SUSHI SAKE occurred at Tsurumi Brewing, an esteemed, established sake brewery in Aichi Prefecture. Tsurumi Brewing began its history in 1873 when founder Teizo Tsurumi, who had been working with dyed goods, opened a sake brewery.

We maintain the traditional methods of production that have been handed down in the Tsushima area, striving to protect the merits of production by hand in the process. At the same time, we are also working to harmonize these methods with more modern systems of quality control and ingenuity, as we strive to create even better sake, and drawing out the depths of flavor inherent in the rice to impart a truly rich taste.

Completed After Trial and Error Under the Tutelage of the Master of a Long-established Restaurant, Founded in 1934

When it came to put the finishing touches on SUSHI SAKE, we turned to the advice of a respected, long-established restaurant, having many fans across Japan. This, we knew, would be critical in our process for the sixth generation of the Tsurumi family who currently operates the company that was founded in 1873.

Using only Yamadanishiki rice, we mill it down to forty percent of its weight. We draw water from an underground source of the Kiso River. Fermentation of the sake occurs at the optimal low temperatures found during the peak of winter, and it is the skill and dedication of the chief brewer, applied slowly over time, that results in the highest quality sake. You will enjoy a subtly rich taste.

Plans to Expand Sales from Shanghai and Hong Kong to Paris and New York

At present, SUSHI SAKE is available at the most established restaurants and department stores in Japan, but starting in December, there will be tastings planned, along with Japanese food, at restaurants in Italy. Moving forward, we plan to expand exports to Shanghai, Hong Kong, Paris, and New York. We will also be increasing availability at restaurants within Japan, as well as sales at department stores and online. Other varieties of SUSHI SAKE in addition to Junmai Daiginjo will be available for sale as well, including Daiginjo, Junmai Ginjo, Ginjo, and Junmai (ginjo refers to the fact that the rice has been milled to 60% of its weight or less).

 

Product Facts

Name  

:

  SUSHI SAKE Kamitsuru Junmai Daiginjo
Price

:

¥12,000 (pre-tax)
Volume

:

1,800 ml
Ingredients

:

Rice, rice malt
Percent alcohol

:

15.5%
Rice used

:

100% Yamadanishiki
Milling degree

:

40%
 

Corporate Overview

Name  

:

  Tsurumi Shuzou Co., Ltd.
Address

:

46 Asahi, Hyaku-cho, Tsushima City, Aichi Prefecture
Representative

:

Masahito Tsurumi
Capitalization

:

¥10 million
Established

:

1873
Incorporation

:

December 1949
Business

:

Production, wholesaling, and retailing of sake, mirin, liqueurs, shochu products, fruit wines, fortified wines, miscellaneous liquors, spirits, beer, and vinegar
Website

:

http://www.tsurumi-jp.com/sushi_sake/en

Contact:

TSURUMI SHUZOU Co., Ltd.
Masahito Tsurumi, +81-567-31-1141
tsurumi@tsurumi-jp.com
Fax: +81-567-32-0586

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye